(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of -21.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Sangamo Therapeutics's revenue in 2024 is $176,232,000.On average, 4 Wall Street analysts forecast SGMO's revenue for 2024 to be $8,289,983,540, with the lowest SGMO revenue forecast at $5,805,511,058, and the highest SGMO revenue forecast at $10,716,490,365. On average, 4 Wall Street analysts forecast SGMO's revenue for 2025 to be $16,807,357,051, with the lowest SGMO revenue forecast at $5,918,222,058, and the highest SGMO revenue forecast at $40,969,554,150.
In 2026, SGMO is forecast to generate $12,965,700,997 in revenue, with the lowest revenue forecast at $9,355,013,042 and the highest revenue forecast at $17,443,369,125.